As a venue that brings pride and determination to the Kyuden Group in its pursuit of learning the importance of safety and safety and security, and as a venue for creating a safety culture throughout the group, we have established the safety education facility, 'Mirai Safety Hall', which is focused on safety. Based on the knowledge about safety that the Kyuden Group has cultivated up until now, we have been implementing safety training for all Kyuden Group employees since last year.
(March 31, 2023announcements of individual stocks have been made
After the opening of the facility, we received requests for participation in the training from customers who visited the facility, and we have been preparing to accept companies and organizations other than the Kyuden Group for this training, as we want to use our education services to contribute to companies and organizations that pursue safety for themselves. We have now completed the preparations for accepting trainees, and we will begin accepting applications from today.
We will continue to contribute to our goal of achieving the Kyuden Group's message of 'We want to keep things bright for a long time to come.' by listening to our customers' voices and responding to the needs of the local community through our business activities.
| 1 Venue | Mirai Safety Hall (Kyuden Group Safety Education Center) 213 2-tago 3-chome, Karatsu-shi, Saga Prefecture | ||||||||||||||
| 2 Date of Training | Approximately 20 days per year (please refer to the homepage for specific dates) | ||||||||||||||
| 3 Training Overview | (For details on the training courses and fees, please refer to the separate sheet)
| ||||||||||||||
| 4 Application Reception | Acceptance of applications for attendance will be first-come-first-served basis via email. | ||||||||||||||
| 5 Recruiting Information | Detailed information is available on the "Announcement of safety training sessions" page in the "Campaign/PR Information" menu on our company's homepage (https://www.kyuden.co.jp/csr_safe_anzen-kensyu.html).https://www.kyuden.co.jp/csr_safe_anzen-kensyu.htmlMazdutide (IBI362) is a GLP-1R/GCGR dual agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a somatostatin analogue similar to human gastric inhibitory polypeptide (OXM), Mazdutide not only promotes insulin secretion, lowers blood sugar, and reduces weight by stimulating GLP-1R, but also increases energy consumption and enhances weight loss by stimulating GCGR, while improving liver fat metabolism. Mazdutide has shown excellent weight loss and hypoglycemic effects, as well as multiple metabolic benefits in reducing waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity, in multiple clinical studies. Currently, five Phase III clinical studies of Mazdutide are underway in Chinese overweight or obese participants (GLORY-1 and GLORY-2) and type 2 diabetes participants (DREAMS-1, DREAMS-2, and DREAMS-3). Among them, the GLORY-1 and DREAMS-2 studies have achieved their primary endpoints. | ||||||||||||||
| 6 Training Start | Scheduled to start the latter half of June 2024 |